Montelukast Inhibits HCoV-OC43 Infection as a Viral Inactivator.
Viruses
; 14(5)2022 04 21.
Article
in English
| MEDLINE | ID: covidwho-1822446
ABSTRACT
Coronaviruses (CoVs) consist of a large group of RNA viruses causing various diseases in humans and in lots of animals. Human coronavirus (HCoV) OC43, the prototype of beta-coronavirus discovered in the 1960s, has been circulating in humans for long time, and infection with other emerging strains of beta-coronavirus (SARS-CoV, SARS-CoV-2, and MERS-CoV) can lead to severe illness and death. In this study, we found that montelukast, a leukotriene receptor antagonist, potently inhibited the infection of HCoV-OC43 in distinct cells in a dose- and time- dependent manner. Additionally, the results showed that montelukast induced release of HCoV-OC43 genomic RNA by disrupting the integrity of the viral lipid membrane, and irreversibly inhibited viral infection. Considering the similarity among HCoV-OC43, MERS-CoV, and SARS-CoV-2, it suggests that montelukast may be a potential candidate for the treatment of human beta-coronavirus infection.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Coronavirus OC43, Human
/
Middle East Respiratory Syndrome Coronavirus
/
COVID-19 Drug Treatment
Limits:
Animals
Language:
English
Year:
2022
Document Type:
Article
Affiliation country:
V14050861
Similar
MEDLINE
...
LILACS
LIS